Trials / Conditions / Liver Cirrhosis, Biliary

Liver Cirrhosis, Biliary

21 registered clinical trials studyying Liver Cirrhosis, Biliary.

Status	Trial	Sponsor	Phase
Completed	Physical Therapy for Liver Cirrhosis NCT04629456	Cairo University	N/A
Completed	Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I) NCT04047160	Kiminori Kimura, MD	Phase 1
Completed	Trial of Psychoeducational and Hypnosis Interventions on the Fatigue Associated With PBC in Women NCT03630718	Assistance Publique - Hôpitaux de Paris	N/A
Terminated	Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Ch NCT03633227	Intercept Pharmaceuticals	Phase 4
Terminated	Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis NCT03476993	Biocad	Phase 2
Terminated	BRIDGE Device for Post-operative Pain Control NCT03265249	Duke University	N/A
Completed	Autologous Bone Marrow Mononuclear Stem Cell for Children Suffering From Liver Cirrhosis Due to Biliary Atresi NCT03468699	Vinmec Research Institute of Stem Cell and Gene Technology	Phase 2
Unknown	Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome NCT02936596	Xiaoli Fan	N/A
Completed	Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital NCT02917408	Xiaoli Fan	—
Terminated	Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis NCT02308111	Intercept Pharmaceuticals	Phase 4
Completed	Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC) NCT00570765	Intercept Pharmaceuticals	Phase 2
Terminated	Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC) NCT00550862	Intercept Pharmaceuticals	Phase 2
Completed	Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis NCT00406237	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 1
Terminated	SAMe to Treat Biliary Cirrhosis Symptoms NCT00125281	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2
Unknown	Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC) NCT00145964	University Health Network, Toronto	—
Completed	Treatment of Cholestatic Pruritus With Sertraline NCT00058903	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2
Unknown	Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis NCT00160940	University Health Network, Toronto	—
Completed	Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis NCT00004842	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 1
Completed	Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis NCT00004784	National Center for Research Resources (NCRR)	Phase 3
Completed	Ursodiol-Methotrexate for Primary Biliary Cirrhosis NCT00006168	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 3
Completed	Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis NCT00004748	National Center for Research Resources (NCRR)	Phase 3